ATP5MK and breast carcinoma: L-ELISA has been designed and implemented for the analysis of two breast cancer biomarkers, CA15-3 (57) and α-1-acid glycoprotein (AGP) (58), showing a higher sensitivity than ELISA, distinguishing breast cancer stages I, IIA, and IIB.